Quick Answer
Aligos Therapeutics, Inc. reported Earnings Per Share Diluted of $2.45 (loss) per share for the year ending 2025.
- Aligos Therapeutics, Inc. showed an increase of +88.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Aligos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $0.78 (loss) per share | Q1 2022: $0.84 (loss) per share | Q2 2022: $0.47 (loss) per share | Q3 2022: $0.44 (loss) per share | Q1 2023: $0.53 (loss) per share | Q2 2023: $0.43 (loss) per share | Q3 2023: $10.37 (loss) per share | Q1 2024: $5.58 (loss) per share | Q2 2024: $0.81 per share | Q3 2024: $3.07 (loss) per share | Q1 2025: $2.11 (loss) per share | Q2 2025: $1.53 (loss) per share | Q3 2025: $3.04 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), Aligos Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 8.9%.
- Historical annual values: Fiscal year 2025: $2.45 (loss) per share | Fiscal year 2024: $20.94 (loss) per share | Fiscal year 2023: $34.20 (loss) per share | Fiscal year 2022: $2.25 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: